Despite significant development of melanoma therapies, death rates remain high. MicroRNAs, controlling posttranscriptionally gene expression, play role in development of resistance to BRAF inhibitors. The aim of the study was to assess the role of miR-410-3p in response to vemurafenib-BRAF inhibitor. FFPE tissue samples of 12 primary nodular melanomas were analyzed. With the use of Laser Capture Microdissection, parts of tumor, transient tissue, and adjacent healthy tissue were separated. In vitro experiments were conducted on human melanoma cell lines A375, G361, and SK-MEL1. IC50s of vemurafenib were determined using MTT method. Cells were transfected with miR-410-3p mimic, anti-miR-410-3p and their non-targeting controls. ER stress was i...
Background: The ability to increase their degree of pigmentation is an adaptive response that confer...
To identify microRNAs potentially involved in melanomagenesis, we compared microRNA expression profi...
The BRAF(V600E) mutation confers constitutive kinase activity and accounts for >90% of BRAF mutation...
42 p.-7 fig.Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic benefi...
The BRAF inhibitors vemurafenib and dabrafenib can be used to treat patients with metastatic melanom...
BRAF inhibitors were approved for the treatment of BRAF-mutant melanoma. However, most patients acqu...
Currently, the treatment of BRAF V600-mutated metastatic melanoma with BRAF inhibitors gives a respo...
Micro-RNAs are important post-transcriptional regulators of cell fate both in normal and disease sta...
Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metas...
Therapy of melanoma patients harboring activating mutations in the BRAF (V-raf murine sarcoma viral ...
Despite increasing amounts of experimental evidence depicting the involvement of non-coding RNAs in ...
MicroRNAs (miRNAs) are attractive therapeutic targets and promising candidates as molecular biomarke...
Cutaneous melanoma is an aggressive skin cancer that emerges from the unrestrained proliferation of ...
My PhD thesis has been directed to the study of the mechanisms responsible for the development of dr...
Abstract Therapy of metastatic melanoma has improved dramatically over the last years thanks to the...
Background: The ability to increase their degree of pigmentation is an adaptive response that confer...
To identify microRNAs potentially involved in melanomagenesis, we compared microRNA expression profi...
The BRAF(V600E) mutation confers constitutive kinase activity and accounts for >90% of BRAF mutation...
42 p.-7 fig.Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic benefi...
The BRAF inhibitors vemurafenib and dabrafenib can be used to treat patients with metastatic melanom...
BRAF inhibitors were approved for the treatment of BRAF-mutant melanoma. However, most patients acqu...
Currently, the treatment of BRAF V600-mutated metastatic melanoma with BRAF inhibitors gives a respo...
Micro-RNAs are important post-transcriptional regulators of cell fate both in normal and disease sta...
Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metas...
Therapy of melanoma patients harboring activating mutations in the BRAF (V-raf murine sarcoma viral ...
Despite increasing amounts of experimental evidence depicting the involvement of non-coding RNAs in ...
MicroRNAs (miRNAs) are attractive therapeutic targets and promising candidates as molecular biomarke...
Cutaneous melanoma is an aggressive skin cancer that emerges from the unrestrained proliferation of ...
My PhD thesis has been directed to the study of the mechanisms responsible for the development of dr...
Abstract Therapy of metastatic melanoma has improved dramatically over the last years thanks to the...
Background: The ability to increase their degree of pigmentation is an adaptive response that confer...
To identify microRNAs potentially involved in melanomagenesis, we compared microRNA expression profi...
The BRAF(V600E) mutation confers constitutive kinase activity and accounts for >90% of BRAF mutation...